Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar will highlight how long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs were evaluated — which is supporting internal research activities at AstraZeneca.
Viewers will hear how library preparation, assessed data quality, and generated important rAAV metrics such as integrity of DNA cargo, truncation events, chimeric transgenes, and levels of co-packaged impurities were performed.
What you will learn:
- Raw material validation through whole plasmid sequencing
- ITR-ITR sequencing of whole AAV genomes and truncation hotspot detection
- Contamination detection in bioreactor batches through sequencing of residual DNA
The webinar features expertise from Heather Stark, Global Segment Marketing Manager, Biopharma, Oxford Nanopore Technologies, Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden, and Bastian Schiffthaler, Senior Data Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden.
An audience Q&A session with the presenters follows the webinar presentations.
Watch the webinar on-demand now!
